Stock Financial Ratios, Dividends, Split History

FSP / Franklin Street Properties Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price8.49
Volume364,400.00
Market Cap ($M)912.54
Enterprise Value ($M)909.98
Book Value ($M)871.29
Book Value / Share8.13
Price / Book1.08
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 107,231,155
Common Stock Shares Outstanding 107,231,155
Preferred Stock Shares Outstanding 0
Weighted Average Number Diluted Shares Outstanding Adjustment 0
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.02
Balance Sheet (mrq) ($M)
Assets1,986.19
Liabilities1,127.28
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Other Real Estate Revenue38,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Syndication Fees Revenue0.00
Real Estate Revenue Net267,265,000.00
Transaction Fees Revenue0.00
Revenues272,588,000.00
Management Fees And Interest Income Operating Revenue5,285,000.00
Operating Income8.42
Net Income-15.94
Earnings Per Share Basic And Diluted-0.15
Cash Flow Statement (mra) ($M)
Cash From Operations95.93
Cash from Investing-5.09
Cash from Financing-5.09
Identifiers and Descriptors
CUSIP35471R106
Central Index Key (CIK)1031316
Related CUSIPS
35471R906

Split History

Stock splits are used by Franklin Street Properties Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Franklin Street (FSP) Signs Lease Deals for One Overton Park

2018-07-05 zacks
Franklin Street Properties Corp. (FSP - Free Report) recently leased around 82,000 square feet of space at its One Overton Park property situated at 3625 Cumberland Boulevard in Atlanta, GA. Reflecting positive sentiments, shares of the company went up 2.56% on Jul 3. The space has been leased to four different tenants, with the largest being leased to Carestream Dental. The company has signed a lease deal for about 54,000 square feet for a period of 130 months. (1-0)

Franklin Street Properties Corp's (FSP) CEO George Carter on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Franklin Street Properties Corp (NYSEMKT:FSP) Q1 2018 Earnings Conference Call May 2, 2018 10:00 AM ET

BRIEF-Franklin Street Properties Corp Q1 Adjusted FFO Per Share $0.16

2018-05-01 reuters
* FRANKLIN STREET PROPERTIES - FOR Q2, INITIATING FFO GUIDANCE IN RANGE OF ABOUT $0.22 TO $0.24 PER SHARE

CUSIP: 35471R106